Piramal Pharma has invested $90m into its two US facilities following the trend towards US onshoring of drug supply.
In conjunction with the 2025 SelectUSA Investment Summit, the company plans to make brownfield expansions to its existing sites, building on its sterile injectable drug manufacturing and R&D capacity.
Piramal Pharma’s Lexington, Kentucky, facility specialises in sterile compounding, liquid filling and lyophilisation for sterile injectable drug products.
The 24,000 sqft expansion adds commercial-scale manufacturing to Piramal's US capabilities, allowing the company to scale-up production of its clients' injectable drug products.
Key additions include:
- A new filling line
- Two commercial-size lyophilises
- A special capping machine
- An external vial washer.
The facility is expected to be completed and functional by 2027.
Riverview, Michigan
Piramal's Riverview, Michigan site is currently responsible for the development and manufacturing of active pharmaceutical ingredients (APIs) and high-potency APIs.
Through the site's expansion, it will now have a commercial-scale suite especially for the development and manfuacture of payload-linkers, which are used to develop popular bioconjugates such as antibody-drug conjugates.
The payload-linker suite will likely be operational before the end of 2025.
These site expansions are expected to generate greater opportunities for integrated ADC projects, playing a vital role in Piramal's integrated ADC development and manufacturing programme, ADCelerate.
“Since its inception, Piramal Pharma Ltd has invested $570 million in its US drug development and manufacturing capabilities,” said Peter DeYoung, CEO of Global Pharma.
“The US is our largest market, where we currently employ approximately 750 people. Expanding the capacities and offerings in these two plants in the US, along with the prior major investments made in our Sellersville PA drug product facility, and our inhalation anaesthesia drug substance and drug product facility in Bethlehem PA, will support our customers who value our offerings in an onshore setting.”